Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Fibrogen Inc CS (FGEN)

Fibrogen Inc CS (FGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Why FibroGen (FGEN) Might Surprise This Earnings Season

FibroGen (FGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

FGEN : 13.84 (+3.28%)
FibroGen to Report Second Quarter 2021 Financial Results

FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2021 financial results on Monday, August 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET...

FGEN : 13.84 (+3.28%)
Eluminex Biosciences Exclusively Licenses FibroGen's Biosynthetic Cornea Technology and Recombinant Collagen III Platform

Eluminex Biosciences (Suzhou) Limited (Eluminex), an ophthalmology-focused biotechnology company headquartered in Suzhou, China with a US-subsidiary office in San Francisco Bay Area, California, announced...

FGEN : 13.84 (+3.28%)
FibroGen (FGEN) Roxadustat Fails to Win FDA Advisory Panel Vote

FibroGen (FGEN) is seeking approval for roxadustat as potential treatment of anemia of chronic kidney disease in the United States. Stock down on unfavorable advisory committee outcome.

AZN : 58.41 (+1.92%)
BIIB : 336.59 (-0.45%)
FGEN : 13.84 (+3.28%)
CTLT : 122.12 (-0.63%)
FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

FibroGen, Inc. (NASDAQ: FGEN) today announced that the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) voted to recommend not approving roxadustat, an...

FGEN : 13.84 (+3.28%)
FibroGen Appoints John Hunter, Ph.D. as Chief Scientific Officer

FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of John Hunter, Ph.D., to the position of Chief Scientific Officer, where he will lead FibroGen's research efforts, leveraging more than 20 years...

FGEN : 13.84 (+3.28%)
Astellas Receives Positive CHMP Opinion for EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced the Committee...

FGEN : 13.84 (+3.28%)
ALPMY : 16.2400 (-0.31%)
Thinking about buying stock in Pieris Pharmaceuticals, Paysafe, Tonix Pharmaceuticals, FibroGen, or Arbutus Biopharma?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PIRS, PSFE, TNXP, FGEN, and ABUS.

ABUS : 3.04 (+10.14%)
FGEN : 13.84 (+3.28%)
TNXP : 0.6935 (+4.58%)
PIRS : 3.76 (+3.01%)
PSFE : 10.29 (+0.19%)
FibroGen and HiFiBiO Announce Transformative Partnership to Advance Next-Generation Therapies for Patients with Cancer and Autoimmune Disease

-- FibroGen Exclusively Licenses HiFiBiO's Galectin-9 Program, and Obtains an Exclusive Option to their CXCR5 and CCR8 Programs

FGEN : 13.84 (+3.28%)
Pancreatic Cancer Action Network Partners With FibroGen To Bring New Experimental Treatment Arm To Adaptive Clinical Trial, Precision Promise(SM)

/PRNewswire/ -- The  (PanCAN), a leading pancreatic cancer advocacy organization, announced today the latest update to its novel clinical trial platform, , with the addition of a new treatment arm by...

FGEN : 13.84 (+3.28%)
Pamrevlumab Included in Pancreatic Cancer Action Network's Adaptive Clinical Trial Platform

FibroGen, Inc. (NASDAQ: FGEN) announced activation of an experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision Promise adaptive trial platform evaluating pamrevlumab [and standard...

FGEN : 13.84 (+3.28%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers. The class action, filed in the United...

FGEN : 13.84 (+3.28%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

New York, New York--(Newsfile Corp. - June 12, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain...

FGEN : 13.84 (+3.28%)
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FGEN, PCT and ARRY

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate...

FGEN : 13.84 (+3.28%)
PCT : 15.81 (+9.11%)
ARRY : 13.74 (+2.23%)
DEADLINE TODAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

Los Angeles, California--(Newsfile Corp. - June 11, 2021) - The Schall Law Firm announced today that they have filed a securities class action lawsuit on behalf of plaintiff Thomas Leonard against FibroGen,...

FGEN : 13.84 (+3.28%)
CLASS ACTION UPDATE for FGEN, CS and CCXI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders...

FGEN : 13.84 (+3.28%)
CS : 10.40 (+1.46%)
CCXI : 15.69 (+2.42%)
Final Day to Actively Participate: FibroGen, Inc. (FGEN) Class Action - Bronstein, Gewirtz & Grossman, LLC

New York, New York--(Newsfile Corp. - June 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or "the Company")...

FGEN : 13.84 (+3.28%)
FGEN FINAL DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN

EQNX::TICKER_START EQNX::TICKER_END

FGEN : 13.84 (+3.28%)
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of FGEN, PCT and WISH

NEW YORK, NY / ACCESSWIRE / June 11, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders...

FGEN : 13.84 (+3.28%)
PCT : 15.81 (+9.11%)
WISH : 9.98 (+3.85%)
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. ("FibroGen" or the "Company") (NASDAQ: FGEN) and certain of its officers.   The class action,...

FGEN : 13.84 (+3.28%)

Barchart Exclusives

Ongoing Chip Shortage Threatens to Slow the Pace Electric Vehicle Production
The ongoing chip shortage may slow the pace of global electric car production. In a conference call on Tuesday, Kurt Sievers, CEO of NXP Semiconductors NV (NXPI ), a major chip supplier to the automotive industry, said “demand is still outstripping supply,” and the tightness will last into next year.... Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar